Botanix Pharmaceuticals Limited (BOT.AX)
| Previous close | 0.0970 |
| Open | 0.0970 |
| Bid | 0.1000 x 38103100 |
| Ask | 0.1050 x 63288200 |
| Day's range | 0.0970 - 0.1050 |
| 52-week range | 0.0520 - 0.1150 |
| Volume | |
| Avg. volume | 2,145,215 |
| Market cap | 118.748M |
| Beta (5Y monthly) | 1.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early preclinical stage studies BOULDER, Colo., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developin
- GlobeNewswire
Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals
Deal includes up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and sales milestone payments, plus tiered earn out payments on net sales to Brickell Sale reflects Brickell’s strategic shift into the immunology and inflammation fields; proceeds will be used to advance Company’s pipeline of recently acquired novel therapies BOULDER, Colo., May 03, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell” o
